Foresite Capital Management VI LLC Acquires 50,000 Shares of Centessa Pharmaceuticals PLC Sponsored ADR $CNTA

Foresite Capital Management VI LLC lifted its holdings in Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) by 3.8% in the 4th quarter, Holdings Channel.com reports. The firm owned 1,364,019 shares of the company’s stock after buying an additional 50,000 shares during the quarter. Centessa Pharmaceuticals makes up about 10.3% of Foresite Capital Management VI LLC’s holdings, making the stock its 4th largest holding. Foresite Capital Management VI LLC’s holdings in Centessa Pharmaceuticals were worth $34,114,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Eagle Health Investments LP acquired a new position in shares of Centessa Pharmaceuticals during the 3rd quarter worth about $2,500,000. SG Americas Securities LLC boosted its stake in shares of Centessa Pharmaceuticals by 1,017.7% in the 4th quarter. SG Americas Securities LLC now owns 263,625 shares of the company’s stock valued at $6,593,000 after purchasing an additional 240,039 shares in the last quarter. Royce & Associates LP acquired a new stake in Centessa Pharmaceuticals in the third quarter valued at approximately $5,999,000. Avoro Capital Advisors LLC boosted its holdings in shares of Centessa Pharmaceuticals by 116.2% during the 3rd quarter. Avoro Capital Advisors LLC now owns 10,808,080 shares of the company’s stock valued at $262,096,000 after acquiring an additional 5,808,080 shares in the last quarter. Finally, Cinctive Capital Management LP acquired a new stake in shares of Centessa Pharmaceuticals during the third quarter worth $2,246,000. Institutional investors own 82.01% of the company’s stock.

Centessa Pharmaceuticals Trading Up 0.1%

NASDAQ:CNTA opened at $39.76 on Tuesday. The firm has a 50 day moving average of $39.64 and a 200 day moving average of $30.96. The company has a quick ratio of 9.53, a current ratio of 9.53 and a debt-to-equity ratio of 0.23. Centessa Pharmaceuticals PLC Sponsored ADR has a 52 week low of $12.05 and a 52 week high of $40.26. The stock has a market capitalization of $6.15 billion, a price-to-earnings ratio of -22.21 and a beta of 1.11.

Centessa Pharmaceuticals (NASDAQ:CNTA) last issued its quarterly earnings data on Tuesday, May 5th. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.14). As a group, sell-side analysts anticipate that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.65 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have weighed in on the company. Lifesci Capital downgraded Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 1st. Stephens cut shares of Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, March 31st. Weiss Ratings restated a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a research report on Monday, April 20th. Truist Financial lowered shares of Centessa Pharmaceuticals from a “buy” rating to a “hold” rating and set a $38.00 price objective for the company. in a report on Monday, April 13th. Finally, Needham & Company LLC cut shares of Centessa Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, March 31st. Four investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Centessa Pharmaceuticals has a consensus rating of “Hold” and an average target price of $41.33.

Insider Activity at Centessa Pharmaceuticals

In other news, insider Karen M. Anderson sold 41,076 shares of the stock in a transaction on Thursday, March 26th. The shares were sold at an average price of $30.12, for a total value of $1,237,209.12. Following the sale, the insider owned 62,085 shares in the company, valued at $1,870,000.20. This represents a 39.82% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 4.09% of the stock is owned by company insiders.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.